Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT)

Publisher： Karger

E-ISSN： 2235-3186|134|4|215-220

ISSN： 1660-8151

Source： Nephron, Vol.134, Iss.4, 2016-07, pp. : 215-220

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Serum Klotho: Relation to Fibroblast Growth Factor-23 and Other Regulators of Phosphate Metabolism in Children with Chronic Kidney Disease

By  

Nephron, Vol. 129, Iss. 4, 2015-03 ,pp. : 293-299

Karger

Access to resources Recommend Favorite

Fibroblast Growth Factor 23 and Matrix-Metalloproteinases in Patients with Chronic Kidney Disease: Are They Associated with Cardiovascular Disease?

By  

Kidney and Blood Pressure Research, Vol. 32, Iss. 4, 2009-10 ,pp. : 276-283

Karger

Access to resources Recommend Favorite

Fibroblast Growth Factor 23 in Chronic Kidney Disease: Bridging the Gap between Bone Mineral Metabolism and Left Ventricular Hypertrophy

By  

Blood Purification, Vol. 31, Iss. 1-3, 2010-12 ,pp. : 26-32

Karger

Access to resources Recommend Favorite

Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients

By  

Cardiorenal Medicine, Vol. 6, Iss. 1, 2015-0 ,pp. : 73-82

Karger

Access to resources Recommend Favorite

Is Fibroblast Growth Factor 23 the New Biomarker for Cardiovascular Mortality in Chronic Kidney Disease Patients?

By  

American Journal of Nephrology, Vol. 45, Iss. 2, 2016-12 ,pp. : 146-148

Karger

Access to resources Recommend Favorite